Literature DB >> 24412525

Separate quality-control measures are necessary for estimation of RNA and methylated DNA from formalin-fixed, paraffin-embedded specimens by quantitative PCR.

Aruna Korlimarla1, Jyothi S Prabhu2, C E Anupama2, Jose Remacle2, Kanu Wahi2, T S Sridhar2.   

Abstract

Estimations of RNA abundance and DNA methylation by quantitative PCR (qPCR) from formalin-fixed, paraffin-embedded (FFPE) tissue specimens are not yet routine in clinical laboratory practice. Excluding specimens with poorly preserved nucleic acids is an important quality-control step for avoiding unreliable results. Because the assays for RNA abundance and DNA methylation have different critical limiting factors, we examined the extent of overlap of excluded specimens for RNA abundance versus methylated DNA. The transcript abundance of three reference genes and of the test gene, estrogen receptor 1 (ESR1), was estimated by SYBR Green qPCR in 250 breast cancer specimens. The estrogen receptor (ER) protein was identified by IHC, and concordance between ESR1 and ER was estimated by Cohen's κ. TaqMan PCR for the ALU-C4 sequence was performed with bisulfite-treated DNA to determine usability in the MethyLight assay. Excluding specimens with mean reference gene CT values exceeding the group mean by >1 SD led to significant improvement of the concordance of ESR1 and ER. Specimens with usable DNA after bisulfite treatment likewise had ALU-C4 CT values of less than the group mean + 1 SD. Samples with low-quality RNA and DNA were partly nonoverlapping. RNA and DNA extracted from the same FFPE block need separate exclusion criteria for qPCR assays of transcript abundance and methylated DNA.
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24412525     DOI: 10.1016/j.jmoldx.2013.11.003

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  9 in total

1.  miR-18a Mediates Immune Evasion in ER-Positive Breast Cancer through Wnt Signaling.

Authors:  Madhumathy G Nair; Apoorva D; Chandrakala M; Snijesh Vp; Sharada Patil; Anupama Ce; Geetashree Mukherjee; Rekha V Kumar; Jyothi S Prabhu; Sridhar Ts
Journal:  Cells       Date:  2022-05-18       Impact factor: 7.666

Review 2.  Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.

Authors:  Margaret L Gulley
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

3.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors.

Authors:  Jyothi S Prabhu; Aruna Korlimarla; Krisha Desai; Annie Alexander; Rohini Raghavan; Ce Anupama; Nandini Dendukuri; Suraj Manjunath; Marjorrie Correa; N Raman; Anjali Kalamdani; Msn Prasad; K S Gopinath; B S Srinath; T S Sridhar
Journal:  J Cancer       Date:  2014-01-23       Impact factor: 4.207

4.  Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.

Authors:  Aruna Korlimarla; Jyothi S Prabhu; Jose Remacle; Savitha Rajarajan; Uma Raja; Anupama C E; B S Srinath; Suraj Manjunath; Gopinath K S; Marjorrie Correa; Prasad M S N; T S Sridhar
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

5.  Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease.

Authors:  Jyothi S Prabhu; Aruna Korlimarla; C E Anupama; Annie Alexander; Rohini Raghavan; Roma Kaul; Krisha Desai; Savitha Rajarajan; Suraj Manjunath; Marjorrie Correa; R Raman; Anjali Kalamdani; Msn Prasad; Shekar Patil; K S Gopinath; B S Srinath; T S Sridhar
Journal:  Transl Oncol       Date:  2017-07-11       Impact factor: 4.243

6.  High expression of integrin β6 in association with the Rho-Rac pathway identifies a poor prognostic subgroup within HER2 amplified breast cancers.

Authors:  Krisha Desai; Madhumathy G Nair; Jyothi S Prabhu; Anupama Vinod; Aruna Korlimarla; Savitha Rajarajan; Radhika Aiyappa; Rohini S Kaluve; Annie Alexander; P S Hari; Geetashree Mukherjee; Rekha V Kumar; Suraj Manjunath; Marjorrie Correa; B S Srinath; Shekhar Patil; M S N Prasad; K S Gopinath; Raman N Rao; Shelia M Violette; Paul H Weinreb; T S Sridhar
Journal:  Cancer Med       Date:  2016-05-17       Impact factor: 4.452

7.  miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.

Authors:  Madhumathy G Nair; Jyothi S Prabhu; Aruna Korlimarla; Savitha Rajarajan; Hari P S; Roma Kaul; Annie Alexander; Rohini Raghavan; Srinath B S; Sridhar T S
Journal:  Cancer Med       Date:  2020-06-16       Impact factor: 4.452

8.  Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.

Authors:  Savitha Rajarajan; Anupama C E; Betsy Jose; Marjorie Correa; Sagar Sengupta; Jyothi S Prabhu
Journal:  Mol Clin Oncol       Date:  2020-09-01

9.  Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.

Authors:  Savitha Rajarajan; Aruna Korlimarla; Annie Alexander; C E Anupama; Rakesh Ramesh; B S Srinath; T S Sridhar; Jyothi S Prabhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.